SynlogicSTU:MIN 28 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:MIN with a GF Score™ of 28/100 and a GF Value™ of €0.15. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Synlogic ranks worse than 104275.18% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Synlogic's Free Cash Flow for the
three
months ended in Mar. 2026 was €-0.49 Mil. Synlogic's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Synlogic's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Synlogic's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Synlogic was -1376.15%. The lowest was -395900.00%. And the median was -3232.13%.
STU:MIN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65 * Ranked among companies with meaningful FCF Margin % only.
Synlogic FCF Margin % Related Terms
Synlogic FCF Margin % Historical Data
* Premium members only.
The historical data trend for Synlogic's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MIN vs CNSP, ELAB, GNPX: FCF Margin % Comparison
For the Biotechnology subindustry, Synlogic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synlogic FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synlogic's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Synlogic's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synlogic (STU:MIN) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Synlogic and its competitors. According to the industry distribution chart, Synlogic ranks #999999 out of 959 companies in the Biotechnology industry.
Is Synlogic's FCF Margin % too high?
Synlogic's current FCF Margin % is 0.00%. Based on the distribution chart, Synlogic ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Synlogic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Synlogic's FCF Margin % compare to CNSP and ELAB?
According to the Biotechnology industry distribution chart, Synlogic ranks #999999 out of 959 companies for FCF Margin %. This places Synlogic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Synlogic and its competitors. Synlogic's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synlogic stock overvalued right now?
Synlogic (STU:MIN) has a current FCF Margin % of 0.00%. The stock's GF Value™ is €0.15, compared to a current price of €3.63 — trading 2320% above its estimated fair value. The current FCF Margin % is 0.00%. Synlogic's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Synlogic (STU:MIN), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synlogic (STU:MIN) Overvalued in 2026?
Based on GuruFocus' analysis, Synlogic stock appears to be overvalued.
The current stock price of €3.63 is trading 2320% above its estimated GF Value™ of €0.15.
Key valuation signals for STU:MIN:
FCF Margin %: 0.00%
GF Value™: €0.15 vs. price of €3.63 (2320% above fair value)
No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
28GF Score
Get the complete analysis for STU:MIN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MIN has been successfully added to your 
